gemcitabine has been researched along with crizotinib in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bang, YJ; Bergethon, K; Camidge, DR; Christensen, J; Clark, JW; Dy, J; Iafrate, AJ; Kim, DW; Kwak, EL; Maki, RG; Ou, SH; Salgia, R; Siwak-Tapp, C; Solomon, BJ; Tan, W; Wilner, KD | 1 |
| Avan, A; Frampton, AE; Funel, N; Giovannetti, E; Maftouh, M; Nicolini, F; Pelliccioni, S; Peters, GJ; Quint, K; Schuurhuis, GJ | 1 |
| Barrière, J; Falk, AT; Ghalloussi, H; Otto, J; Poudenx, M | 1 |
| Avan, A; Boggi, U; Campani, D; Caretti, V; Fuchs, D; Funel, N; Galvani, E; Giovannetti, E; Honeywell, RJ; Lagerweij, T; Maftouh, M; Peters, GJ; Schuurhuis, GJ; Van Tellingen, O; Verheul, HM; Würdinger, T | 1 |
| Besse, B; Gazzah, A; Remon, J; Soria, JC | 1 |
| Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM; Solca, F | 1 |
| Avan, A; Funel, N; Giovannetti, E; Gomez, VE; Griffioen, AW; Leon, LG; Rovithi, M; Verheul, HM; Wurdinger, T | 1 |
| Li, J; Li, W; Liang, L; Liu, Z; Wang, Y; Xu, F; Xu, H; Yang, G; Yang, L; Ying, J; Zhang, Q; Zhang, S | 1 |
| Bai, J; Guo, H; Lei, J; Li, S; Yang, J; Zhang, S | 1 |
10 other study(ies) available for gemcitabine and crizotinib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Topics: Aged; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crizotinib; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Amplification; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Treatment Outcome | 2011 |
Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromatography, Liquid; Crizotinib; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mass Spectrometry; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines | 2013 |
Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cisplatin; Crizotinib; Deoxycytidine; DNA Mutational Analysis; Fatal Outcome; Female; Gemcitabine; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Oncogene Proteins, Fusion; Pyrazoles; Pyridines; Translocation, Genetic | 2012 |
Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Crizotinib; Deoxycytidine; Female; Gemcitabine; Humans; Inactivation, Metabolic; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-Small Cell Lung Cancer Patient.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Osteoarthritis; Protein Kinase Inhibitors; Pyrazoles; Pyridines | 2015 |
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Crizotinib; Cyclic S-Oxides; Deoxycytidine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Ligands; MAP Kinase Signaling System; Mutation; Pancreatic Neoplasms; Phenotype; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor | 2016 |
Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing.
Topics: Adenocarcinoma; Animals; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Chickens; Chorioallantoic Membrane; Crizotinib; Deoxycytidine; DNA Mutational Analysis; Drug Evaluation, Preclinical; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 6; Luminescent Measurements; MicroRNAs; Models, Biological; Pancreatic Neoplasms; Sequence Analysis, DNA; SOX9 Transcription Factor; Tumor Cells, Cultured | 2017 |
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Docetaxel; Female; Gemcitabine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncogene Fusion; Paclitaxel; Pemetrexed; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Retrospective Studies; Treatment Outcome | 2020 |
Fabrication of polymer-based self-assembly nanocarriers loaded with a crizotinib and gemcitabine: potential therapeutics for the treatment of endometrial cancer.
Topics: Crizotinib; Deoxycytidine; Drug Carriers; Endometrial Neoplasms; Female; Gemcitabine; Humans; Nanoparticles; Polyesters; Polyethylene Glycols; Polymers | 2022 |